
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Год журнала: 2024, Номер 20(2), С. 133 - 142
Опубликована: Апрель 19, 2024
In recent years, there has been an interest in studying the specifics of relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia insomnia are important risk factors for insulin resistance, obesity, MetS, type 2 diabetes mellitus with a degree influence similar to traditional factors. Thus, treatment dyssomnia is one key tasks prevention MetS. The regulation circadian rhythms by exogenous intervention (in particular, use melatonergic drugs) likely play central role MEL acts as powerful antioxidant that can cross blood-brain barrier, suppress oxidative stress, chronic inflammation, interact gut microbiome. From clinical point view, imbalance may indicate “darkness deficit”. It proven neurohormone systemic effects due its mechanisms action, potential course many diseases. Currently, drugs approved exclusively insomnia, jetlag, depression accompanied disorders. However, potentially therapeutic properties neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune allergic increasing need products prompted search safe but environmentally friendly medicines. reported phytomelatonin have advantages related improved bioavailability efficacy. purpose this review analyze relationship dyssomnia, MEL. was conducted Scopus, Science Direct (from Elsevier), PubMed, including MEDLINE databases. keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive apnea”, “melatonin”. We manual bibliography publications identify research results eluded during online search.
Язык: Английский